Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Sponsor
Sichuan Cancer Hospital and Research Institute
Study ID
NCT04725448
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Toripalimab — DRUG
    240mg, ivgtt, d1, every 3 weeks until disease progress or intolerable toxicity, up to 2 years of administration
  • Bevacizumab — DRUG
    7.5mg/kg, ivgtt, d1, every 3 weeks, up to 2 years of administration
  • Nab-paclitaxel — DRUG
    260mg/m2,d1 or 130mg/m2,d1,8, ivgtt, every 3 weeks, up to 6 cycles
  • Carboplatin — DRUG
    AUC=4～5, d1, ivgtt, every 3 weeks, up to 6 cycles

Study Details

This study aimed to evaluate the efficacy and safety of first-line Toripalimab combined with bevacizumab, nab-paclitaxel and carboplatin in the treatment of patients with advanced pulmonary sarcomatoid carcinoma.

Key Dates

First listed
Jan 26, 2021
Start date
Apr 6, 2021
Status verified
Apr 2021
Primary completion
Mar 1, 2022
Completion
Nov 30, 2023

Study Design

Enrollment
27 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin
    Drugs: Toripalimab, 240mg (6ml)/bottle, ivgtt, d1, q3w, administration until PD or death, the longest use time is two years. Drugs: Bevacizumab, 7.5mg/kg, ivgtt, d1, q3w,the longest use time is two years. Drugs: Nab-paclitaxel, 260mg/m2,ivgtt,d1 or 130mg/m2,ivgtt,d1,8, q3w, up to six cycles. Drugs: Carboplatin, AUC=4～5, ivgtt, d1, q3w, up to six cycles.

Primary Outcome Measure

Progress Free Survival(PFS) [ Time Frame: up to 2 years ]

Central Contacts

Related Studies